N Engl J Med·· 1 day agoScore69
Ianalumab for the Treatment of Patients with Sjögren's Disease.
In brief
NEPTUNUS-1 and NEPTUNUS-2 enrolled 275 and 504 patients with active Sjögren's disease, respectively. Ianalumab 300 mg monthly reduced disease activity at week 48.
Source: N Engl J Med · doi.org